Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharmaceuticals switzerland gmbh - säure-nitricum 70 pro hundert, säure aceticum glaciale, säure oxalicum dihydricum, acid lacticum 90 %, kupfer(ii) nitras trihydricus - lösung - säure-nitricum 70 pro hundert 580.66 mg, säure aceticum glaciale 41.08 mg, säure oxalicum dihydricum 57.32 mg, acid lacticum 90 % 4.55 mg, kupfer(ii) nitras trihydricus 0.048 mg, excipiens ad-lösung für 1 ml. - topische behandlung von warzen - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharmaceuticals switzerland gmbh - säure-nitricum 70 pro hundert, säure aceticum glaciale, säure oxalicum dihydricum, zinci nitras hexahydricus - lösung - acidum nitricum 70 per centum 268.5 mg, acidum aceticum glaciale 10.2 mg, acidum oxalicum dihydricum 29.3 mg, zinci nitras hexahydricus 3 mg, aqua purificata ad solutionem pro 0.5 ml. - gutartige zervix-läsionen - synthetika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris healthcare gmbh (8009064) - essigsäure 99%; milchsäure; oxalsäure 2 h<2>o; kupfer(ii)-nitrat; salpetersäure ((mit angaben zur konzentration)) - lösung - essigsäure 99% (00122) 8,2 milligramm; milchsäure (00203) 0,9 milligramm; oxalsäure 2 h<2>o (10097) 11,5 milligramm; kupfer(ii)-nitrat (10285) 0,0095 milligramm; salpetersäure ((mit angaben zur konzentration)) (10001) 116,1 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lege artis pharma gmbh & cokg (3082493) - metacresol (ph.eur.); lidocainhydrochlorid 1 h<2>o; paraformaldehyd - paste (dent.) - teil 1 - paste (dent.); metacresol (ph.eur.) (01498) 45 milligramm; lidocainhydrochlorid 1 h<2>o (01693) 370 milligramm; paraformaldehyd (02889) 460 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

septodont gmbh (3165144) - 4-chlorphenol; racemischer campher; paraformaldehyd; lidocain - paste zur anwendung am zahnfleisch - teil 1 - paste zur anwendung am zahnfleisch; 4-chlorphenol (01199) 80 milligramm; racemischer campher (13033) 130 milligramm; paraformaldehyd (02889) 180 milligramm; lidocain (00973) 360 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

meckel-spenglersan gmbh - immunserum; tuberkulin - all other therapeutic produ

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

meckel-spenglersan gmbh - streptococcus spec. /enterococcus (auszug, produkte); streptococcus pneumoniae; staphylococcus spec.; tuberkulin - all other therapeutic produ

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

meckel-spenglersan gmbh - streptococcus spec. /enterococcus (auszug, produkte); immunserum; tuberkulin - all other therapeutic produ

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

meckel-spenglersan gmbh - tuberkulin; immunserum; streptococcus pneumoniae - all other therapeutic produ

Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunsuppressiva - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. die behandlung der schweren, aktiven und progressiven rheumatoiden arthritis bei erwachsenen, die zuvor nicht mit methotrexat behandelt. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduziert die rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und verbessert die körperliche funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita gegeben werden kann als monotherapie im falle einer unverträglichkeit gegenüber methotrexat oder wenn die fortsetzung der behandlung mit methotrexat ungeeignet ist (für die wirksamkeit in der monotherapie siehe abschnitt 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduziert die rate der progression der peripheren gelenkschäden, wie gemessen, durch die x-ray bei patienten mit polyarticular symmetrischen subtypen der erkrankung (siehe abschnitt 5. 1) und verbessert die körperliche funktion. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.